174 related articles for article (PubMed ID: 32706598)
1. Ocular and systemic pharmacokinetics of brimonidine and brinzolamide after topical administration in rabbits: comparison between fixed-combination and single-drug formulations.
Suzuki G; Kunikane E; Shigemi W; Shinno K; Kozai S; Kurata M; Kawamura A
Curr Eye Res; 2021 Mar; 46(3):380-386. PubMed ID: 32706598
[TBL] [Abstract][Full Text] [Related]
2. Vitreous and aqueous concentrations of brimonidine following topical application of brimonidine tartrate 0.1% ophthalmic solution in humans.
Takamura Y; Tomomatsu T; Matsumura T; Takihara Y; Kozai S; Arimura S; Yokota S; Inatani M
J Ocul Pharmacol Ther; 2015 Jun; 31(5):282-5. PubMed ID: 25918904
[TBL] [Abstract][Full Text] [Related]
3. The Relationship of Brimonidine Concentration in Vitreous Body to the Free Concentration in Retina/Choroid Following Topical Administration in Pigmented Rabbits.
Shinno K; Kurokawa K; Kozai S; Kawamura A; Inada K; Tokushige H
Curr Eye Res; 2017 May; 42(5):748-753. PubMed ID: 27854122
[TBL] [Abstract][Full Text] [Related]
4. Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow.
Kadam RS; Jadhav G; Ogidigben M; Kompella UB
Drug Metab Dispos; 2011 Sep; 39(9):1529-37. PubMed ID: 21673129
[TBL] [Abstract][Full Text] [Related]
5. Ocular and Systemic Pharmacokinetics of Brimonidine and Timolol After Topical Administration in Rabbits: Comparison Between Fixed-Combination and Single Drugs.
Suzuki G; Kunikane E; Shinno K; Kozai S; Kurata M; Kawamura A
Ophthalmol Ther; 2020 Mar; 9(1):115-125. PubMed ID: 31953739
[TBL] [Abstract][Full Text] [Related]
6. Real-life experience of using brinzolamide/brimonidine fixed drop combination in a tertiary glaucoma centre.
Kóthy P; Holló G
Int Ophthalmol; 2020 Feb; 40(2):377-383. PubMed ID: 31650353
[TBL] [Abstract][Full Text] [Related]
7. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation.
Lusthaus JA; Goldberg I
Expert Opin Drug Saf; 2017 Sep; 16(9):1071-1078. PubMed ID: 28656780
[TBL] [Abstract][Full Text] [Related]
8. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.
Katz G; Dubiner H; Samples J; Vold S; Sall K
JAMA Ophthalmol; 2013 Jun; 131(6):724-30. PubMed ID: 23579344
[TBL] [Abstract][Full Text] [Related]
9. Ocular pharmacokinetics of intravitreally administered brimonidine and dexamethasone in animal models with and without blood-retinal barrier breakdown.
Shen J; Durairaj C; Lin T; Liu Y; Burke J
Invest Ophthalmol Vis Sci; 2014 Feb; 55(2):1056-66. PubMed ID: 24448267
[TBL] [Abstract][Full Text] [Related]
10. Ocular Distribution of Brimonidine and Brinzolamide after Topical Instillation of a 0.1% Brimonidine Tartrate and 1% Brinzolamide Fixed-Combination Ophthalmic Suspension: An Interventional Study.
Orii Y; Kunikane E; Yamada Y; Morioka M; Iwasaki K; Arimura S; Mizuno A; Inatani M
J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445209
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Ocular and Systemic Pharmacokinetics of Brinzolamide in Rabbits After Intracameral, Topical, and Intravenous Administration.
Naageshwaran V; Ranta VP; Gum G; Bhoopathy S; Urtti A; Del Amo EM
J Pharm Sci; 2021 Jan; 110(1):529-535. PubMed ID: 33035542
[TBL] [Abstract][Full Text] [Related]
12. Ocular pharmacokinetics profile of different indomethacin topical formulations.
Bucolo C; Melilli B; Piazza C; Zurria M; Drago F
J Ocul Pharmacol Ther; 2011 Dec; 27(6):571-6. PubMed ID: 22059858
[TBL] [Abstract][Full Text] [Related]
13. Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine.
Kim SN; Ko SA; Park CG; Lee SH; Huh BK; Park YH; Kim YK; Ha A; Park KH; Choy YB
Mol Pharm; 2018 Aug; 15(8):3143-3152. PubMed ID: 30020792
[TBL] [Abstract][Full Text] [Related]
14. Brinzolamide/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension.
Greig SL; Deeks ED
Drugs Aging; 2015 Mar; 32(3):251-60. PubMed ID: 25732405
[TBL] [Abstract][Full Text] [Related]
15. Preclinical overview of brinzolamide.
DeSantis L
Surv Ophthalmol; 2000 Jan; 44 Suppl 2():S119-29. PubMed ID: 10665514
[TBL] [Abstract][Full Text] [Related]
16. Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%.
Nguyen QH; McMenemy MG; Realini T; Whitson JT; Goode SM
J Ocul Pharmacol Ther; 2013 Apr; 29(3):290-7. PubMed ID: 23425430
[TBL] [Abstract][Full Text] [Related]
17. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
[TBL] [Abstract][Full Text] [Related]
18. Mucoadhesive microparticles with a nanostructured surface for enhanced bioavailability of glaucoma drug.
Park CG; Kim YK; Kim MJ; Park M; Kim MH; Lee SH; Choi SY; Lee WS; Chung YJ; Jung YE; Park KH; Choy YB
J Control Release; 2015 Dec; 220(Pt A):180-188. PubMed ID: 26478018
[TBL] [Abstract][Full Text] [Related]
19. Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: An interventional study.
Orii Y; Kunikane E; Yamada Y; Morioka M; Iwasaki K; Arimura S; Mizuno A; Inatani M
PLoS One; 2022; 17(12):e0277313. PubMed ID: 36454807
[TBL] [Abstract][Full Text] [Related]
20. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.
Day DG; Hollander DA
Curr Med Res Opin; 2008 May; 24(5):1435-42. PubMed ID: 18402717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
